AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof:



(I)

wherein

X represents O or S;

R^1 represents hydrogen, halogen, hydroxy, nitro, cyano, C_{1-6} alkoxy carbonyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkanoyl, phenyl, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen;

R^2 represents hydrogen, halogen, hydroxy, nitro, cyano, C_{1-6} alkoxy carbonyl, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkanoyl, phenyl, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen, or C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen;

R^3 represents hydrogen, halogen, hydroxy, nitro, cyano, amino, carboxy, tetrazolyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, C_{1-6} alkanoyl, C_{1-6} alkanoylamino, C_{1-6} alkyl optionally substituted by mono-, di- or tri- halogen or hydroxy;

R^4 represents



,

wherein:

R^{71} represents hydrogen, or C_{1-6} alkyl optionally substituted by amino, hydroxy, carboxy, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6} alkyl) amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di-oxo; and

Z^1 represents $-[CH_2]_p-$, wherein p is ~~represents an integer~~ ~~1 or~~ 2.

2. (Currently Amended) The compound of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1,

wherein R^4 represents



,

wherein:

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di-oxo.

3. (Currently Amended) The compound of claim 1, wherein the derivative is of the formula (I-b), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof:



(I-b)

wherein:

R^1 represents fluoro, chloro, bromo, iodo, or nitro;

R^2 represents fluoro, chloro, bromo, iodo, or nitro;

R^3 represents acetyl, cyano, or tetrazolyl;

R^4 represents



wherein:

R^{71} represents hydrogen, or C_{1-6} alkyl optionally substituted by amino, hydroxy, carboxy, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo;

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl, wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di-oxo; and

Z^1 represents $-[CH_2]_p-$, wherein p is ~~represents an integer 1 or~~ 2.

4. (Currently Amended) The compound of claim 3, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof,

wherein:

R^1 represents fluoro, chloro or bromo;

R^2 represents fluoro, chloro or bromo;

R^3 represents cyano;

R^4 represents



wherein:

R^{72} represents hydrogen, carboxy, C_{1-6} alkanoyl, amino, (C_{1-6}alkyl)amino, di(C_{1-6}alkyl)amino, N-(C_{1-6}alkyl)amino carbonyl, C_{1-6} alkyl optionally substituted by hydroxy, carboxy, or mono-, di- or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di- or tri- halogen, pyrrolidinyl or piperidinyl wherein said pyrrolidinyl and piperidinyl are optionally substituted by mono- or di- oxo.

5. (Previously Presented) A compound of claim 1, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof, wherein said compound is selected from the group consisting of:

(R)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;

(S)-N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;

N-(1-aza-bicyclo[2.2.2]oct-3-yl)-2-(3,5-dichloro-phenylsulfanyl)-5-nitro-benzenesulfonamide; and

(R)-5-cyano-2-(3,5-dichlorophenoxy)-N-(2-(2,5-dioxopyrrolidin-1-yl)ethyl)-N-(1-aza-bicyclo[2.2.2]oct-3-yl)benzenesulfonamide.

6. (Currently Amended) A pharmaceutical composition comprising a compound of claim 1, its tautomeric or stereoisomeric form, or a physiologically acceptable salt

thereof as an active ingredient, and one or more pharmaceutically acceptable excipients.

7. (Canceled).

8. (Previously Presented) The pharmaceutical composition of claim 6, wherein said compound, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a CCR3 antagonist.

9. – 13. (Canceled).

14. (Currently Amended) A method of treating ~~The method of claim 13, wherein said disorder or disease is selected from the group consisting of~~ asthma, allergic rhinitis or lung granuloma, ~~allergic diseases, and autoimmune pathologies~~ comprising administering a compound of claim 1 or its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.

15. (Canceled).

16. (Currently Amended) The method of claim 14[[13]], wherein said compound, its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is formulated with one or more pharmaceutically acceptable excipients.

17. – 19. (Canceled).

20. (Currently Amended) The pharmaceutical composition of claim 6[[7,]] wherein the excipient is an inert substance such as a carrier, a diluent, a flavoring agent, a sweetener, a lubricant, a solubilizer, a suspending agent, a binder, a tablet disintegrating agent or an encapsuling agent.

21. (Previously Presented) The method of claim 16, wherein the excipient is an inert substance such as a carrier, a diluent, a flavoring agent, a sweetener, a lubricant, a solubilizer, a suspending agent, a binder, a tablet disintegrating agent or an encapsuling agent.